Introduction
B-ALL is a malignancy of precursor B cells with the highest incidence among children [1] . Although most children with B-ALL can be cured by current chemotherapy, relapsed patients remain at a very high risk of death, and adult patients with ALL have even worse clinical outcomes [2] . In addition to genetic abnormalities, a dysregulated immune system facilitates the immune evasion of cancer cells in hematologic malignancies, including B-ALL [3] [4] [5] . Understanding the mechanism of immune dysfunction in B-ALL will benefit the discovery of effective immunotherapy.
MDSCs are a heterogeneous population of progenitor and immature myeloid cells that acquire potent immunosuppressive functions [6] . In mice, MDSCs are defined as CD11b +
Gr1
+ cells [7] . Human MDSCs usually express the common myeloid markers CD33 and CD11b but lack expression of HLA-DR [8] . Because of their heterogeneous nature, MDSCs can be further divided into 2 subsets: M-MDSCs and G-MDSCs or polymorphonuclear MDSCs [9] . These 2 subsets differ in many aspects, including cellular morphology, gene profiling, tissue distribution, and suppressive functions [10, 11] . M-MDSCs suppress T cell responses in an Ag-nonspecific manner, predominantly by up-regulating arginase-1 and iNOS [12] . G-MDSCs suppress Agspecific T cell responses by enhancing the generation of ROS [13, 14] .
The expansion and activation of MDSCs are driven by soluble factors secreted from the tumor microenvironment. These factors include IL-6, granulocyte-Mf CSF, and vascular endothelial growth factor, among others [15] . The expansion of MDSCs represents a major driver of immunotolerance in cancerbearing hosts, including solid tumors and hematologic malignancies [16] [17] [18] . The expanded MDSCs exert strong suppressive effects on antitumor immunity by inhibiting effector immune cells and/or inducing the generation of regulatory immune cells or immunosuppressive cytokines [19] . Direct effects of MDSCs on tumor invasion and metastasis have also been demonstrated [20] . Therefore, depletion of MDSCs could enhance the effects of current clinical therapy, including chemotherapy and immunotherapy, even in late-stage cancers [21] . Targeting MDSCs through different paths represents a novel strategy for tumor immunotherapy.
In addition to various solid tumors, MDSC expansion has been observed in hematologic malignancies, including MM, leukemia, and lymphoma [22, 23] . Targeting MDSCs in hematologic malignancies has shown efficacy in delaying disease progression [21] . In patients with chronic myeloid leukemia, higher levels of MDSCs could interfere with the effect of immunotherapy. CD14 + HLA-DR low/2 MDSCs were increased significantly in patients with chronic lymphocytic leukemia [24] . They suppressed T cell responses and induced T regs through increased IDO [25] . The number of MDSCs is correlated with tumor progression and prognosis in patients with chronic myeloid leukemia [24] . MM is also a B cell-derived malignancy. The frequencies of highly suppressive CD14 + MDSCs are increased in the BM and blood of patients with MM, as well as in a mouse model of MM [23] . The frequency of MDSCs correlates with disease progression of MM and induces systemic immunosuppression in patients with MM [26] . The role of MDSCs in the pathogenesis of B-ALL, however, remains largely unknown.
In the present study, we report that G-MDSCs were elevated in the peripheral blood and BM from patients with B-ALL at diagnosis. The level of G-MDSCs decreased in patients entering remission after therapy and was positively correlated with prognostic markers of B-ALL. B-ALL-derived G-MDSCs were functionally suppressive, which was mediated though the production of ROS and activation of STAT3 signaling. Therefore, our data suggest that the immunosuppressive mechanism of MDSCs may represent a potential immune therapeutic target for B-ALL disease treatment.
MATERIALS AND METHODS

Ethics statement
This research was approved by the ethics review board of Guangzhou Women and Children's Medical Center and the Ethics Review Board of Sun Yat-Sen University. Written, informed consents were provided by participants and/or their legal guardians.
Patients and healthy donors
Patients with B-ALL recruited at Department of Hematology Oncology, Guangzhou Women and Children's Medical Center. Peripheral blood and BM samples were collected from individuals who were diagnosed with B-ALL before treatment (B-ALL-DX, n = 43). The enrolled patients were followed for 29-d of clinical therapy, including those who achieved remission (n = 35) and those who did not (n = 8). Both blood and BM samples were collected before and during the therapy. Remission standard was MRD ,1%. Patients with no remission did not response to chemotherapy and had positive results for MRD. The age-matched healthy controls (n = 21) had no reported history of hematologic disorders, infections, or other diseases. The basic characteristics of patients with B-ALL and healthy donors are outlined in Supplemental Table 1 .
PBMCs isolation and flow cytometric analysis
PBMCs and BM cells were isolated from whole blood by Ficoll centrifugation, and low-density fraction from PBMCs was analyzed immediately [27] . The following anti-human Abs were purchased from Thermo Fisher Scientific (Waltham, MA, USA): CD11b-FITC, CD33-PE, CD14-PE-Cy7, CD15-eFluor450, CD45-PE-Cy7, CD-19-APC-Cy7, HLA-DR-PE-Cy5, CD4-PE, CD8-PE-Cy5, CD3-PE-Cy7, and their corresponding isotope controls. The cell phenotype was analyzed by flow cytometer (BD LSR fortessa; BD Biosciences, San Jose, CA, USA), and the data were analyzed with the FlowJo 10.0 software package (TreeStar Inc, Ashland, OR, USA). At least 200,000 total live cells were evaluated by flow cytometry. A FACS Aria II (BD Biosciences) was used for flow cytometric sorting. The strategy for MDSC sorting was to gate HLA-DR 2/low CD11b + CD33 int/high cells from live PBMCs. In some experiment, G-MDSCs were sorted from PBMCs; then, the remaining PBMCs were used for the T cell proliferation assay.
T cell proliferation assay
T cell proliferation was evaluated by CFSE dilution. PBMCs or purified T cells (1 3 10 6 cells/ml) were labeled with CFSE (3 mM) (Thermo Fisher Scientific,
Waltham and then were stimulated with anti-CD3/CD28 Abs (5 mg/ml) (Thermo Fisher Scientific). After coculture alone or with MDSCs for 3 d, T cell proliferation was evaluated by flow cytometric analysis. T cells without stimulation were used as the negative control.
Arginase activity assay
Briefly, cells were lysed with 0.1% Triton X-100 for 30 min, followed by the addition of 25 mM Tris-HCl and10 mM MnCl 2 . The enzyme was activated by heating for 10 min at 56°C. Arginine hydrolysis was performed by incubating the lysate with 0.5 M L-arginine at 37°C for 2 h. The urea concentration was measured at 540 nm after the addition of alpha-isonitrosopropiophenone (dissolved in 100% ethanol), followed by heating at 95°C for 30 min.
ROS production
The experiment was performed following the manufacturer' procedures. Cells (5 3 10 5 cells) were incubated at 37°C in the presence of 1 l mM CM-H2DCFDA (Thermo Fisher Scientific) for 30 min and were then labeled with fluorescence-conjugated Abs against CD33 and CD11b. The ROS content in MDSCs was analyzed by flow cytometry.
ELISA assay
The production of IFN-g in culture supernatants was determined by ELISA assay, following the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).
qRT-PCR
RNA was extracted with an RNase Minikit, and cDNA was synthesized using a SuperScript III reverse transcriptase kit (Qiagen, Valencia, CA, USA). PCR was performed with gene-specific primers for each target (Supplemental Table 2 ). Briefly, reactions were performed in triplicate using SYBR Green (Takara, Otsu, Japan). Standard curves were generated from 10-fold serial dilutions of known concentrations of a synthetic transcript. Triplicate reactions were run, and the number of template copies was calculated based on the standard curve.
Transwell assays
The 
Coculture of G-MDSC and NK cells
Healthy NK cells were isolated and coculture with G-MDSC from patients with B-ALL or the corresponding population from healthy controls at a 1:1 ratio for 24 h in the presence of IL-2 (20 IU/ml), and their effector function was analyzed by flow cytometry.
Intracellular staining
Intracellular staining of pSTAT3 (phospho Tyr705) was performed following the manufacturer's protocol (Cell Signaling Technology, Beverly, MA, USA). Cells (5 3 10 5 cells) were fixed with formaldehyde to stabilize the cell membrane and were permeabilized using BD Fix & Perm solution (BD Biosciences). After washing, the cells were then stained with Alexa Fluor 488-conjugated pSTAT3 and analyzed by flow cytometry.
Statistics
Clinical and immunologic parameters were compared by nonparametric Mann-Whitney U tests. For in vitro experiments, statistical analyses were performed using unpaired or paired t tests. Correlations among different parameters were analyzed using a Spearman's rank test. GraphPad Prism (version 5.0a; GraphPad Software, La Jolla, CA, USA) and SPSS (version 17.0; SPSS Inc., Chicago, IL, USA) software were used. P values , 0.05 were considered significant. Fig. 1A ). Additional markers, including CD14, CD15, CD66b, and Mf CSF receptor, were used for confirmation (Supplemental Fig. 1B) . The results showed that both the frequency and the absolute cell counts of immature G-MDSCs in peripheral blood were elevated significantly in patients with B-ALL at diagnosis, when compared with healthy controls (Fig. 1A and B) . Meanwhile, the levels of G-MDSCs from patients with B-ALL entering remission were markedly decreased after therapy, reaching levels comparable with those in healthy controls ( Fig. 1A and B) . For patients without remission, G-MDSCs remained consistently higher after therapy, in comparison with healthy controls (Fig. 1A and B) . In contrast with the changes in G-MDSCs, no noticeable differences were observed in M-MDSCs from the different groups, including the frequencies and absolute cell numbers (Fig. 1A-C) . Consistent with the results observed in peripheral blood, there were similar changes in G-MDSCs and M-MDSCs from the BM of patients with B-ALL ( Fig.1D-F) . Wright-Giemsa staining exhibited that G-MDSCs from patients with B-ALL showed typical immature cellular morphology (Supplemental Fig. 1C ). Expression levels and absolute cell numbers of CD15 + cells in whole blood were unchanged between healthy controls and patients with B-ALL, supporting the theory that the elevation was specific for G-MDSCs, not for other granulocyte populations (Supplemental Fig. 1D ). These observations indicated that systematic elevation of G-MDSCs may be associated with the clinical therapeutic response in childhood patients with B-ALL.
RESULTS
Elevation of G-MDSCs in peripheral blood and BM from patients with B-ALL
The frequencies of G-MDSCs correlate with prognostic markers of B-ALL
To evaluate the clinical significance of G-MDSCs in B-ALL, we evaluated the correlation between their numbers and B-ALL disease prognostic markers. MRD is an essential and important predictor of relapse in B-ALL and provides an assessment of the residual leukemic burden. Studies indicate that MRD is an indispensable prognostic parameter in pediatric B-ALL [29] . We found that the dynamic changes of G-MDSCs were closely correlated with the changes of MRD proportion in patients with B-ALL during the course of clinical therapy, in both the PBMC and BM ( Fig. 2A and B) . In contrast, no correlation was observed between the changes of M-MDSCs and MRD in either peripheral blood or BM ( Fig. 2C and D) . In addition to MRD, the frequencies of CD20 + and blast cells are two other prognostic indicators in pediatric B-ALL [30] . Analysis revealed that the frequency of G-MDSCs, but not M-MDSCs, correlated positively with MRD levels, the frequencies of blast cells, and CD20 + cells in B-ALL at diagnosis in patients without therapy (B-ALL-DX) (Fig.  2E-G) . These results supported the theory that G-MDSC levels were intimately correlated with disease prognostic markers in B-ALL and indicated that G-MDSCs may present a novel immunologic marker of disease progression in B-ALL.
G-MDSCs from patients with B-ALL are immunosuppressive
One of the most important characteristics of MDSCs is their immunosuppressive function, which contributes to the immunotolerance of the tumor microenvironment [12] . We next examined whether G-MDSCs from patients with B-ALL were immunosuppressive toward T cells and NK cells, the most important effector immune cells. PBMCs were isolated from patients with B-ALL, G-MDSCs were sorted by flow cytometry, and the remaining PBMC were evaluated for T cell responses upon anti-CD3/CD28 stimulation. The results showed that depletion of G-MDSCs from PBMCs significantly enhanced the proliferation of both CD4 + and CD8 + T cells (Fig. 3A) . This suggested that the presence of G-MDSCs in B-ALL suppressed T cell responses. Coculture of G-MDSCs with T cells at different ratios further demonstrated that the suppression of T cells by G-MDSCs was dose dependent, including effects on proliferation and IFN-g secretion ( Fig. 3B and C) . However, M-MDSCs from the PBMCs of patients with B-ALL did not suppress T cell responses (Supplemental Fig. 2A) . Furthermore, G-MDSCs from the BM of patients with B-ALL also displayed immunosuppressive activity toward T cells (Supplemental Fig. 2B ), and G-MDSCs from patients with remission lost their suppressive function ( Supplementary Fig. 2C ). One potential explanation for these finding is that chemotherapy may change the activation of G-MDSCs. Transwell experiments showed that separation of G-MDSCs from T cells eliminated their suppressive activity (Fig.  3D ). This indicated that the effect of G-MDSCs on T cells required direct cell-cell contact. The impairment of NK cell function facilitates the evasion of innate immune surveillance in ALL [3] . We next studied whether B-ALL-derived G-MDSCs contributed to the dysfunction of NK cells. Coculture of NK cells with B-ALL-derived G-MDSCs led to significant impairment in the function of NK cells from healthy donors. This included CD107a degranulation (CD56 + CD3 2 CD107 + ) and the production of effector cytokines, such as IFN-g (CD56 + CD3 2 IFN-g + ) and TNF-a (CD56 + CD3 2 TNF-a + ) (Fig. 3E) . These results demonstrated that B-ALL-derived G-MDSCs were immunosuppressive and may contribute to the immunotolerant status of patients with B-ALL.
B-ALL-derived G-MDSCs suppress T cell responses in an ROS-dependent manner
We next investigated the mechanism of G-MDSC-mediated immune suppression. Changes in L-arginine and its metabolic products are important mechanisms in the suppressive activity of MDSCs under tumor and other pathologic conditions. Therefore, we measured the level of ROS and the activity of arginase in G-MDSCs from patients with B-ALL. The ROS level was increased significantly in G-MDSCs from patients with B-ALL, when compared with healthy controls (Fig. 4A) . No obvious difference was observed in arginase activity of G-MDSCs from patients with B-ALL and healthy controls (Fig. 4B) . Gene expression analysis showed that p47 phox , a molecule related to ROS production, was up-regulated in B-ALL-derived G-MDSCs (Fig. 4C and D and Supplemental Fig. 3A) . No changes were observed in the expression of arginase-1 and iNOS, which are responsible for the activity of arginase and NO production, respectively ( Fig. 4C and  D) . The ROS inhibitor, N-acetyl-L-cysteine, almost completely abrogated the immunosuppressive activity of G-MDSCs in a T cell coculture system, including T cell proliferation (Fig. 4E) and IFN-g production (Fig. 4F) . Other inhibitors, including the arginase inhibitor N w -hydroxy-nor-L-arginine, iNOS inhibitor L-NG-monomethyl arginine (L-NMMA), as well as L-arginine supplementation, failed to display any effects (Fig. 4E and F) . These results demonstrated that B-ALL-derived G-MDSCs suppress T cell responses in an ROS-dependent manner.
STAT3 signaling regulates the suppressive activity of B-ALL-derived G-MDSCs
We next investigated which signaling pathway was responsible for the enhanced ROS production and activation of G-MDSCs in patients with B-ALL. STAT3 signaling is a key mechanism regulating the expansion and activation of MDSCs under tumor and other conditions [10] . Flow cytometric analysis revealed a significantly higher level of pSTAT3 in B-ALL-derived G-MDSCs, in comparison with the corresponding control (Fig. 5A) . The mRNA and protein expression of S100A9, a downstream transcriptional target of STAT3, was up-regulated in B-ALL-derived G-MDSCs (Fig. 5B and C and Supplemental Fig. 3B ). Administration of cucurbitacin I (JSI-124), a potent inhibitor of pSTAT3, decreased ROS production (Fig. 5D ) and the suppressive activity (Fig. 5E ) 
DISCUSSION
Because of their potent immunosuppressive function, MDSCs are recognized as active players in the tumor-promoting microenvironment [31] . Solid tumors and distant tumor tissues including the tumor, stroma, and activated immune cells, can secrete cytokines and regulate myeloid cell differentiation in the BM, where MDSCs are generated and activated [32] . MDSCs then migrate from the BM and suppress antitumor immunity in both tumor tissue and other organs [19] . For hematologic malignancies, cancer cells derived from hematopoietic cells can interact with myeloid progenitor cells in the BM, thereby potentially promoting MDSC expansion and activation directly [33, 34] . Therefore, the mechanism underlying MDSC expansion or activation in hematologic tumors may be distinct from that for solid tumors. In human MM, there is a bidirectional interaction between MDSCs and cancer cells [23] . B-ALL is derived from malignant precursor B cells within the BM. How tumor cells directly drive the expansion of MDSCs in BM, or whether expanded MDSCs could directly affect tumor cell growth in B-ALL, deserves further investigation. Answering these questions will facilitate our understanding of the complicated network between immune cells and cancer cells within the BM microenvironment for hematologic malignancies.
MDSCs from different types of tumors have distinct surface markers and molecules that make MDSC-based immunotherapy in humans challenging. Nevertheless, the potential therapeutic value of targeting MDSCs in hematologic malignancies has attracted attention in recent years [35, 36] . Either CD14 + M-MDSCs or CD15 + CD14
2 G-MDSCs are elevated in other types of human hematologic tumors [37] . In the current study, only G-MDSC numbers were increased in patients with B-ALL, further supporting that changes of MDSCs in human cancers are dependent on tumor type. The potential mechanism is that In tumor-bearing hosts, MDSCs from different tissues (such as peripheral blood and tumor tissue) have distinct gene expression or functionality [6] . This indicates that the tissue microenvironment may modulate the biology of MDSCs. In our study, we found that G-MDSCs were elevated in both the peripheral blood and BM. The functions of MDSCs from BM were comparable with those from the peripheral blood. Because of the few cells available from BM, we did not evaluate whether G-MDSCs from BM also generated greater amount of ROS and up-regulated STAT3 signaling. Overall, the increased numbers of MDSCs contributed to the immunosuppressive microenvironment of BM and may directly facilitate the immune evasion of tumor cells. Understanding the differences of MDSCs located in BM and other tissues from B-ALL deserves further investigation.
The clinical significance of MDSCs is apparent by the close correlation between MDSC levels and disease progression, as well as clinical stages, in various solid tumors and hematologic malignancies [38] . Yang et al. [39] reported that a G-MDSC deficiency of IRF7 correlated with tumor metastasis in patients with hepatoma carcinoma and concluded that these cells have a unique role in patients with tumors. Also, in patients with chronic myeloid leukemia, mesenchymal stem cells may activate G-MDSCs and suppress T lymphocyte-mediated leukemia surveillance [40] . These reports show that G-MDSCs have a critical role in regulating immune escape in the tumor microenvironment. Here, we show that the levels of G-MDSCs are correlated dynamically with the important clinical parameters of B-ALL, such as positive MRD, CD20, and blast cells, and the response of patients to therapy. Specifically, G-MDSCs from patients in remission lost their suppressive function, which helped us to understand the effect of G-MDSCs in mediating immune evasion in patients with B-ALL. A better understanding of the role of the immune system in leukemia is critical. Our results imply that G-MDSCs could be an independent parameter in predicting the progression of B-ALL. Impairment in the function of T and NK cells, as well as the induction of T regs , also participates in the pathogenesis of B-ALL [3] . Uncovering the association among MDSCs and other types of immune cells will facilitate the understanding of immune dysregulation in B-ALL.
In summary, we report that G-MDSCs were elevated significantly in patients with B-ALL. G-MDSC numbers correlated with disease progression and clinical therapeutic responses. STAT3 signaling-mediated ROS generation drove the activation of B-ALL-derived MDSCs. These observations suggest that targeting MDSCs is a promising strategy for treatment of patients with B-ALL. 
